After college at RPI, University of Pennsylvania, and a small stint at Princeton, I joined Bristol-Myers Squibb. There I worked in three different groups. The first group was a scale-up technology group, the second, a crystallization group, and the third a process development group. For family reasons, I moved to Pfizer in 2006, where I was a group lead in the crystallization group of Materials Science. After several reorganizations, I am now leading the effort to bring Continuous Crystallization to Chemical Research and Development.
Specialties: Crystallization, polymorphism, organic synthesis process development and scaleup, on-line analytical instrumentation and methods, crystallization technology. API/Drug Product interface and continuous processing.